The Delegation of the European Union acknowledges that
the EU decision on checks of vaccine exports from the EU has
caused concern in New Zealand.
Over the weekend, the
European Union adopted a set of targeted and temporary
measures to control vaccine exports until the end of March
2021. This means, in practice, European-based pharmaceutical
companies must seek authorisation before they export
The EU is taking this step to
ensure it receives its pre-paid vaccines as expected. The EU
has paid for Covid-19 vaccines with a number of
pharmaceutical companies, but is only receiving one in four
of its paid doses.
Doses that were initially allotted
for the EU may have been exported to third countries. This
delays the vaccination rollout to a region that is gravely
afflicted by Covid-19 with thousands of people dying every
The EU is concerned by the lack of transparency
around the ways some companies are operating and wants to
achieve greater openness for the global distribution of
vaccines. We expect this transparency will benefit New
Zealand and ensure it receives its full quota on time as per
its own agreements.
As well, we want to prevent the
trafficking and reselling for profit of vaccines. Data on
the supply chain will achieve this.
The European Union
remains fully committed to international solidarity and its
international obligations. The EU has contributed €500
million (NZ$8.47 million) to COVAX to ensure fair and
universal access to Covid-19 vaccines. Vaccine exports as
part of humanitarian assistance or COVAX will
From the beginning, the EU has supported the
rapid development and production of several vaccines against
COVID-19 with a total of €2.7 billion (NZ$4.54 billion).
Prior authorisation is in keeping with the EU’s commitment
to full and fair deployment of